Sellas Vaccine Extends Survival in Hard-to-Treat Blood Cancer Trial

Sellas Life Sciences’ galinpepimut-S vaccine reduced the risk of death by 41% in a Phase 3 AML trial, with median survival of 24 months.

Sellas Vaccine Extends Survival in Hard-to-Treat Blood Cancer Trial
Credit: SELLAS Life Sciences Group
Already have an account? Sign in.